Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 31 |
| List of Tables | 28 | 4 |
| List of Figures | 32 | 1 |
| Introduction | 33 | 1 |
| Global Markets Direct Report Coverage | 33 | 1 |
| Type 1 Diabetes (Juvenile Diabetes) Overview | 34 | 1 |
| Therapeutics Development | 35 | 2 |
| Pipeline Products for Type 1 Diabetes (Juvenile Diabetes) Overview | 35 | 1 |
| Pipeline Products for Type 1 Diabetes (Juvenile Diabetes) Comparative Analysis | 36 | 1 |
| Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Development by Companies | 37 | 10 |
| Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Investigation by Universities/Institutes | 47 | 2 |
| Type 1 Diabetes (Juvenile Diabetes) Pipeline Products Glance | 49 | 4 |
| Late Stage Products | 49 | 1 |
| Clinical Stage Products | 50 | 1 |
| Early Stage Products | 51 | 1 |
| Unknown Stage Products | 52 | 1 |
| Type 1 Diabetes (Juvenile Diabetes) Products under Development by Companies | 53 | 13 |
| Type 1 Diabetes (Juvenile Diabetes) Products under Investigation by Universities/Institutes | 66 | 3 |
| Type 1 Diabetes (Juvenile Diabetes) Companies Involved in Therapeutics Development | 69 | 106 |
| AbGenomics International, Inc. | 69 | 1 |
| Adocia | 70 | 1 |
| AiCuris GmbH and Co KG | 71 | 1 |
| Alteogen Inc. | 72 | 1 |
| Amarantus Bioscience Holdings, Inc. | 73 | 1 |
| Ambrx, Inc. | 74 | 1 |
| AntriaBio, Inc. | 75 | 1 |
| Aphios Corporation | 76 | 1 |
| APT Therapeutics, Inc. | 77 | 1 |
| Araim Pharmaceuticals, Inc. | 78 | 1 |
| Argos Therapeutics, Inc. | 79 | 1 |
| Artery Therapeutics, Inc. | 80 | 1 |
| Astellas Pharma Inc. | 81 | 1 |
| AstraZeneca Plc | 82 | 1 |
| Athersys, Inc. | 83 | 1 |
| Atlantic Bio Sci LLC | 84 | 1 |
| Axxam SpA | 85 | 1 |
| Beta-Cell NV | 86 | 1 |
| Biocon Limited | 87 | 1 |
| Biogenomics Limited | 88 | 1 |
| BioLineRx, Ltd. | 89 | 1 |
| BioLingus AG | 90 | 1 |
| BioTherapeutics Inc. | 91 | 1 |
| BirchBioMed Inc | 92 | 1 |
| Boehringer Ingelheim GmbH | 93 | 1 |
| Caladrius Biosciences Inc | 94 | 1 |
| Cancer Prevention Pharmaceuticals, Inc. | 95 | 1 |
| Carlina Technologies SAS | 96 | 1 |
| Compugen Ltd. | 97 | 1 |
| ConjuChem, LLC | 98 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 99 | 1 |
| Dance Biopharm Inc. | 100 | 1 |
| Diabetology (Products) Ltd | 101 | 1 |
| DiaMedica Inc. | 102 | 1 |
| Diamyd Medical AB | 103 | 1 |
| Diasome Pharmaceuticals, Inc. | 104 | 1 |
| Dompe Farmaceutici S.p.A. | 105 | 1 |
| Eli Lilly and Company | 106 | 1 |
| enGene, Inc | 107 | 1 |
| Ensol Biosciences Inc. | 108 | 1 |
| EpiVax, Inc. | 109 | 1 |
| Escape Therapeutics, Inc. | 110 | 1 |
| Evotec AG | 111 | 1 |
| F. Hoffmann-La Roche Ltd. | 112 | 1 |
| Fate Therapeutics, Inc. | 113 | 1 |
| Generex Biotechnology Corporation | 114 | 1 |
| GeNeuro SA | 115 | 1 |
| Geropharm | 116 | 1 |
| Gilead Sciences, Inc. | 117 | 1 |
| GlaxoSmithKline Plc | 118 | 1 |
| Grifols, S.A. | 119 | 1 |
| Heptares Therapeutics Limited | 120 | 1 |
| Iltoo Pharma | 121 | 1 |
| ImmusanT, Inc. | 122 | 1 |
| Innopharmax Inc. | 123 | 1 |
| Intrexon Corporation | 124 | 1 |
| Islet Sciences, Inc. | 125 | 1 |
| Johnson &Johnson | 126 | 1 |
| Kadimastem Ltd. | 127 | 1 |
| Kamada Ltd. | 128 | 1 |
| Kasiak Research Private Limited | 129 | 1 |
| KPI Therapeutics, Inc. | 130 | 1 |
| Lexicon Pharmaceuticals, Inc. | 131 | 1 |
| Ligand Pharmaceuticals, Inc. | 132 | 1 |
| Lonestar Heart, Inc. | 133 | 1 |
| MacroGenics, Inc. | 134 | 1 |
| Medestea Research &Production S.p.A. | 135 | 1 |
| MedImmune LLC | 136 | 1 |
| Medy-Tox Inc. | 137 | 1 |
| Merck &Co., Inc. | 138 | 1 |
| Meridigen Biotech Co., Ltd. | 139 | 1 |
| MidaSol Therapeutics LP | 140 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 141 | 1 |
| Novo Nordisk A/S | 142 | 1 |
| Noxxon Pharma AG | 143 | 1 |
| Oramed Pharmaceuticals, Inc. | 144 | 1 |
| Orgenesis Inc | 145 | 1 |
| OSE Immunotherapeutics | 146 | 1 |
| Paras Biopharmaceuticals Finland Oy | 147 | 1 |
| Parvus Therapeutics, Inc. | 148 | 1 |
| Pathfinder Cell Therapy Inc | 149 | 1 |
| Pfizer Inc. | 150 | 1 |
| PharmaCyte Biotech, Inc. | 151 | 1 |
| PharmaIN Corporation | 152 | 1 |
| Prometheon Pharma, LLC | 153 | 1 |
| Purzer Pharmaceutical Co., Ltd. | 154 | 1 |
| RedHill Biopharma Ltd. | 155 | 1 |
| REGiMMUNE Corporation | 156 | 1 |
| Sanofi | 157 | 1 |
| SEKRIS Biomedical, Inc. | 158 | 1 |
| Selecta Biosciences, Inc. | 159 | 1 |
| Semma Therapeutics Inc. | 160 | 1 |
| Sevion Therapeutics, Inc. | 161 | 1 |
| Strongbridge Biopharma plc | 162 | 1 |
| Therapix Biosciences Ltd. | 163 | 1 |
| Thermalin Diabetes, LLC | 164 | 1 |
| Toleranzia AB | 165 | 1 |
| Transgene Biotek Limited | 166 | 1 |
| UCB SA | 167 | 1 |
| Unicyte AG | 168 | 1 |
| United Therapeutics Corporation | 169 | 1 |
| ViaCyte, Inc. | 170 | 1 |
| Visionary Pharmaceuticals, Inc. | 171 | 1 |
| XL-protein GmbH | 172 | 1 |
| XOMA Corporation | 173 | 1 |
| Zensun (Shanghai) Sci &Tech Co., Ltd. | 174 | 1 |
| Type 1 Diabetes (Juvenile Diabetes) Therapeutics Assessment | 175 | 26 |
| Assessment by Monotherapy Products | 175 | 1 |
| Assessment by Combination Products | 176 | 1 |
| Assessment by Target | 177 | 10 |
| Assessment by Mechanism of Action | 187 | 10 |
| Assessment by Route of Administration | 197 | 2 |
| Assessment by Molecule Type | 199 | 2 |
| Drug Profiles | 201 | 390 |
| (clarithromycin + clofazimine + rifabutin) Drug Profile | 201 | 8 |
| (cyclosporine + lansoprazole) Drug Profile | 209 | 1 |
| (dulaglutide + insulin glargine) Drug Profile | 210 | 1 |
| (Glucagon-Like Peptide-1 + insulin human) Drug Profile | 211 | 1 |
| (insulin aspart + insulin aspart protamine) Drug Profile | 212 | 1 |
| (insulin glargine + insulin lispro) Drug Profile | 213 | 3 |
| (insulin glargine + liraglutide) Drug Profile | 216 | 1 |
| (insulin human + pramlintide acetate) Drug Profile | 217 | 1 |
| (insulin lispro + insulin lispro protamine) Drug Profile | 218 | 1 |
| 2-AMD Drug Profile | 219 | 1 |
| 4548G-05 Drug Profile | 220 | 1 |
| AB-101 Drug Profile | 221 | 2 |
| AbGn-168H Drug Profile | 223 | 2 |
| ABS-11 Drug Profile | 225 | 1 |
| AGS-010 Drug Profile | 226 | 2 |
| AI-001 Drug Profile | 228 | 1 |
| AIC-284 Drug Profile | 229 | 1 |
| AKS-091 Drug Profile | 230 | 1 |
| albiglutide Drug Profile | 231 | 4 |
| aldesleukin Drug Profile | 235 | 1 |
| aldesleukin Drug Profile | 236 | 1 |
| ALM Drug Profile | 237 | 1 |
| alpha-1 proteinase inhibitor (human) Drug Profile | 238 | 1 |
| alpha-1 proteinase inhibitor (human) Drug Profile | 239 | 5 |
| AMRS-001 Drug Profile | 244 | 9 |
| Antibody for Neurodegenerative Diseases and Diabetes Drug Profile | 253 | 1 |
| APH-0907 Drug Profile | 254 | 1 |
| BetaGRAFT Drug Profile | 255 | 1 |
| Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes Drug Profile | 256 | 1 |
| Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes Drug Profile | 257 | 1 |
| BL-001 Drug Profile | 258 | 1 |
| BL-9020 Drug Profile | 259 | 2 |
| Bone Marrow Stem Cells + Ig-GAD2 Drug Profile | 261 | 1 |
| Borapetoside A Drug Profile | 262 | 1 |
| BP-2002 Drug Profile | 263 | 1 |
| BSN-302 Drug Profile | 264 | 1 |
| BT-12 Drug Profile | 265 | 1 |
| C-10 Drug Profile | 266 | 2 |
| C-peptide + insulin human + proinsulin human Drug Profile | 268 | 1 |
| canagliflozin Drug Profile | 269 | 7 |
| Capsulin IR Drug Profile | 276 | 1 |
| Cell Therapy + CXCL12 Drug Profile | 277 | 1 |
| Cell Therapy for Type 1 Diabetes Drug Profile | 278 | 2 |
| Cell Therapy for Type 1 Diabetes Drug Profile | 280 | 1 |
| Cell Therapy for Type 1 Diabetes Drug Profile | 281 | 1 |
| Cell Therapy for Type 1 Diabetes and Type 2 Diabetes Drug Profile | 282 | 1 |
| Cell Therapy for Type-1 Diabetes and Type-2 Diabetes Drug Profile | 283 | 3 |
| Cellular Immunotherapy for Rheumatoid Arthritis and Type 1 Diabetes Drug Profile | 286 | 1 |
| Cellular Immunotherapy for Type 1 Diabetes Drug Profile | 287 | 1 |
| Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome Drug Profile | 288 | 1 |
| CGEN-15001 Drug Profile | 289 | 3 |
| Chlorolog Drug Profile | 292 | 1 |
| cibinetide Drug Profile | 293 | 3 |
| CLBS-03 Drug Profile | 296 | 3 |
| Coltelizumab Drug Profile | 299 | 1 |
| dalazatide Drug Profile | 300 | 5 |
| dapagliflozin propanediol Drug Profile | 305 | 7 |
| Diamyd Drug Profile | 312 | 9 |
| Dipep Drug Profile | 321 | 1 |
| DM-199 Drug Profile | 322 | 4 |
| Drug for Rheumatoid Arthritis, Type 1 and Type 2 Diabetes Drug Profile | 326 | 1 |
| Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes Drug Profile | 327 | 1 |
| Drug to Agonize GLP-1 for Type I and Type II Diabetes Drug Profile | 328 | 1 |
| Drug to Agonize IL-2 Receptor for Type 1 and Type 2 Diabetes Drug Profile | 329 | 1 |
| Drug to Inhibit DPP-1 for Type I and Type II Diabetes Drug Profile | 330 | 1 |
| Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health Drug Profile | 331 | 1 |
| Drug to Inhibit SGLT-2 for Type I and Type II Diabetes Drug Profile | 332 | 1 |
| Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders Drug Profile | 333 | 1 |
| Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes Drug Profile | 334 | 1 |
| DV-100 Drug Profile | 335 | 1 |
| DV-200 Drug Profile | 336 | 1 |
| DWP-457 Drug Profile | 337 | 1 |
| EFFI-7H Drug Profile | 338 | 2 |
| eflornithine hydrochloride Drug Profile | 340 | 2 |
| EG-02 Drug Profile | 342 | 1 |
| empagliflozin Drug Profile | 343 | 8 |
| Epi-13 Drug Profile | 351 | 1 |
| EVT-770 Drug Profile | 352 | 1 |
| exenatide biobetter Drug Profile | 353 | 1 |
| FR-104 Drug Profile | 354 | 3 |
| Gene Therapy for Type I Diabetes Drug Profile | 357 | 1 |
| Glucostem Drug Profile | 358 | 1 |
| GNbAC-1 Drug Profile | 359 | 3 |
| golimumab Drug Profile | 362 | 8 |
| GS-548202 Drug Profile | 370 | 1 |
| Harmine Drug Profile | 371 | 1 |
| HDV-I Drug Profile | 372 | 1 |
| HP-211 Drug Profile | 373 | 1 |
| Hydrogel Basal Insulin Drug Profile | 374 | 1 |
| Ins-PBA-F Drug Profile | 375 | 1 |
| insulin aspart Drug Profile | 376 | 1 |
| insulin aspart Drug Profile | 377 | 1 |
| insulin aspart Drug Profile | 378 | 1 |
| insulin degludec Drug Profile | 379 | 1 |
| insulin glargine Drug Profile | 380 | 2 |
| insulin glargine Drug Profile | 382 | 1 |
| insulin glargine Drug Profile | 383 | 1 |
| insulin glargine Drug Profile | 384 | 2 |
| insulin glargine Drug Profile | 386 | 1 |
| insulin glargine Drug Profile | 387 | 1 |
| insulin human Drug Profile | 388 | 7 |
| insulin human Drug Profile | 395 | 2 |
| insulin human Drug Profile | 397 | 1 |
| insulin human Drug Profile | 398 | 1 |
| insulin human Drug Profile | 399 | 1 |
| insulin human Drug Profile | 400 | 1 |
| insulin human Drug Profile | 401 | 2 |
| insulin human Drug Profile | 403 | 1 |
| insulin human Drug Profile | 404 | 1 |
| insulin human Drug Profile | 405 | 1 |
| insulin human Drug Profile | 406 | 1 |
| insulin human Drug Profile | 407 | 1 |
| insulin human Drug Profile | 408 | 1 |
| insulin human Drug Profile | 409 | 1 |
| insulin human Drug Profile | 410 | 1 |
| insulin human Drug Profile | 411 | 1 |
| insulin human U100 Drug Profile | 412 | 3 |